Bottom Line This study is one of the more provocative breast oncology signals of the year
It might not make you faster generally, but it could help to enhance your performance and energy
Discussion In this study, we observed that 12.9% of the patients with type 2 diabetes concomitant with AKD, who were not treated with GLP-1 RAs, experienced mortality within 5 years after discontinuing dialysis for AKI
Those medicines all share a common feature
The US GLP-1 user population is large and growing, and current government policy and drug-provider pricing strategies are breaking down adoption barriers and may make it grow faster, said Rick Miller, partner and marketing effectiveness practice lead at Big Chalk
While animal studies and early clinical reports are promising, its important to note that BPC-157 peptide therapy is not yet FDA-approved for weight loss or any specific medical condition, and large-scale human studies are still needed